Document Detail


Immunogenicity, efficacy and adverse events of adalimumab in RA patients.
MedLine Citation:
PMID:  17006705     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To assess the immunogenicity of adalimumab, a human anti-TNF-alpha mAb, we evaluated the formation of antibodies to adalimumab, efficacy and adverse events among 15 patients with highly active rheumatoid arthritis. Four patients were treated with adalimumab as monotherapy, and 11 patients with concomitant DMARDs. Disease activity was measured by DAS28. The antibodies were detected by ELISA. Thirteen (87%) patients withdrew from therapy within 45 weeks and overall 13 (87%) patients showed antibodies to adalimumab including 11 patients who withdrew from therapy. In four patients without concomitant DMARDs and in nine patients with concomitant DMARDs, we detected anti-adalimumab antibodies. Overall, five of seven patients with adverse drug reactions and all nine patients with lack of efficacy were associated with the formation of antibodies. Two antibody-positive patients developed an exantheme. The results indicate that adalimumab is, in spite of its fully human sequences, immunogenic and induces antibodies in a high rate of adalimumab-treated patients.
Authors:
Niko K Bender; Christoph E Heilig; Benjamin Dröll; Jessica Wohlgemuth; Franz-Paul Armbruster; Bernhard Heilig
Related Documents :
17581335 - Axillary lymph node visualization on f-18 fdg pet body scans in patients with rheumatoi...
1564275 - Nonrheumatoid closed rupture of extensor carpi ulnaris tendon.
19208685 - First signs and symptoms of spondyloarthritis--data from an inception cohort with a dis...
9290265 - Soluble tumor necrosis factor receptor in serum of patients with arthritis.
18419785 - Incidence of radiation thyroiditis and thyroid remnant ablation success rates following...
19941265 - update: alpha-1-antitrypsin deficiency. summary of a scientific symposium at the confer...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2006-09-28
Journal Detail:
Title:  Rheumatology international     Volume:  27     ISSN:  0172-8172     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-09     Completed Date:  2007-10-16     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  269-74     Citation Subset:  IM    
Affiliation:
Rheumapraxis Heidelberg, Wielandstr. 20, 69120, Heidelberg, Germany. n.bender@rheumapraxis-heidelberg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Anti-Idiotypic / immunology*
Antibodies, Monoclonal / adverse effects,  immunology*
Antibodies, Monoclonal, Humanized
Arthritis, Rheumatoid / drug therapy*
Female
Humans
Male
Middle Aged
Treatment Failure
Chemical
Reg. No./Substance:
0/Antibodies, Anti-Idiotypic; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic scleros...
Next Document:  Leiomyosarcoma of the inferior vena cava